- Peptide Substrates
- Binding Proteins
- Secondary Antibodies
- Regulatory proteins
- 脂类激酶
- 双加氧酶与蛋白质
- 脂质底物
- E2
- Assay Buffer and Co-factors
- Methyltransferases
- Acetyltransferases
- Transcription Proteins
- COVID-19 ELISA Kits
- Tau Proteins
- Microtubule & Actin Associated Proteins
- Carbohydrate Substrates
- COVID-19 Proteins
- Chemokines
- 标记抗体
- 授予称号
- E3
- 【桥头火锅】品牌介绍→桥头火锅底料_重庆桥头火锅_买购网
- SignalChem|生产厂家|价格信息
- signalchem
- IL4 Gene GeneCards | IL4 Protein | IL4 Antibody
- 代理产品SignalchemSignalchem
- 重组人IL11说明书
- cell signaling 三天审稿完毕,小修! 论文投稿 交流 ...
- ...SignalChem一级代理,SignalChem中国代理,SignalChem公司_环保...
- “不积极”英语是什么?unactive吗?
- “不积极”英语是什么?unactive吗?
- 苏州蚂蚁淘实验试剂有限公司17年8月份销售过的产品1苏州蚂蚁淘...
- SignalChem安徽代理 |产品目录|代理商|蚂蚁淘进口试剂平行进口
Overview:
Cell Division Control protein 1 (CDK1) is a highly conserved protein serine kinase. CDK1 is a catalytic subunit of the conserved eukaryotic protein kinase complex called that M-Phase Promoting Factor, which plays a key role in regulation of the cell cycle (1). CDK1 is essential for the completion of START, the controlling event in the cell cycle that is required to initiate mitosis. The ability of CDK1 to exercise control over the cell cycle is dependent upon the phosphorylation of Tyr15 in cdc2 (2). CDK1 expression in brain has been linked to neurogenesis and apoptosis (3,4). In addition, CDK1 is a potential pharmaceutical target for prostate cancer therapy (5).
References:
1. Maller, J.L.: Mitotic control. Curr Opin Cell Biol 1991 3:269-275.2. Nakamizo, A. et al: Suppression of cdc2 dephosphorylation at the tyrosine 15 residue during nitrosourea-induced G2M phase arrest in glioblastoma cell lines. J Neurooncol 2002 59:7-13.3. Konishi Y et al: The E2F-cdc2 cell-cycle pathway specifically mediates activity deprivation-induced apoptosis of postmitotic neurons. J Neurosci 2003 23:1649-1658.4. Dranovsky, A. et al. cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology. Neurobiol Aging 2001 22:517-528.5. Rigas, A.C. et al: Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene 2007 Dec 6;26(55):7611-9.


